Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

No Pauses For Pagoclone: Indevus Moving To Phase III For Stuttering

This article was originally published in The Pink Sheet Daily

Executive Summary

The anxiolytic would be the first drug indicated for the condition.

You may also be interested in...



Indevus Rides High On Double Good News

No new trials for testosterone therapy, FDA says; separate Teva deal sweetens the pot.

Indevus Rides High On Double Good News

No new trials for testosterone therapy, FDA says; separate Teva deal sweetens the pot.

Indevus Gains Supprelin LA With Purchase Of Valera

Indevus also expects to out-license Valera's early stage pipeline, as well as several of its own products.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS064218

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel